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Cost-Effectiveness	of	Multidisciplinary	Management	and	Exercise	Training	in	Heart	
Failure	Treatment	Anji	Yi	
Introduction	
       As one of the major public health problems, heart failure (HF) is affecting more than 
3 million patients in the United States [1]. Around 20% of all hospitalizations in 
populations older than 60 years of age in developed countries are caused or 
complicated by HF [2]. HF has been incurring above $38 billion annual health care 
expenditures a year, of which $23 billion is for hospital stays [3], accounting for 1-2% of 
total health care expenditure [4] and two third of hospitalization costs in the United 
States and Europe [5]. HF not only ranks the first in the most common discharge 
diagnoses among elderly patients, and shows extremely high readmission rates after 
index hospitalization, with up to 44% of patients re-hospitalized within six months of 
discharge [6].  
        In addition to pharmacologic treatments, several behavioral interventions have 
been receiving more attention and documented to improve quality of life and reduce 
hospitalization of HF patients [7]. The major interventions reported include 
multidisciplinary management programs (MMP) [8] and exercise training programs 
(ETP) [9], and both of these two methods have been proved to be effective in improving 
the survival of HF patients. One [10] cost-effectiveness analysis, based on a systematic 
literature review of clinical trials on MMP [5], estimated an incremental cost-
effectiveness ratio (ICER) of $9,700 per life-year gained in MMP as compared to usual 
care (UC). There are two published cost-effectiveness analyses on exercise training 
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based on two clinical trials [11, 12], respectively, and the ICERs were $1,773 and 
$26,462 per life-year saved, respectively. However, no comparison has been made 
between the cost-effectiveness of the MMP and ETP; thus it is still unclear that which 
one is more desirable in terms of the cost-effectiveness in HF treatment. Therefore, a 
cost-effectiveness analysis comparing these two interventions is needed to determine 
the most cost-effective intervention for HF patients. 
	
Methods	
Study	population	and	interventions									We	used	published	data	from	several	literature	reviews	of	randomized	controlled	trials	on	MMP	and	ETP,	as	shown	in	Table	1.	The	study	population	in	the	used	studies	was	patients	aged	56-80	years	old	with	heart	failure	diagnosed	from	hospital	in	North	America,	Europe,	Australia,	or	New	Zealand.	The	key	components	of	MMP	included	disease	education	for	patients	and	continuing	support,	such	as	psychological	support,	dietary	and	social	services	consultation,	and	regular	follow-ups	by	nurse,	primary	care	physician,	or	pharmacist,	or	through	telephone	[5].	While	ETP,	as	explained	by	the	name	itself,	focused	on	frequent	hospital-based	exercise	training,	under	the	supervision	of	professional	medical	exercise	trainer,	as	well	as	regular	cardiopulmonary	stress	test	during	the	training	and	basic	components	of	MMP	[13].	Therefore,	ETP	included	exercise	training	in	addition	to	the	management	care	provided	by	MMP.		
Structure	of	the	model	
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	Figure	1.	Markov	model	diagram.		Patients	occupy	and	transit	among	Markov	states,	including	living,	hospitalization,	living	after	hospitalization,	and	death.		
	
								We	developed	a	Markov	model	with	eight	transitional	states	to	simulate	long-term	follow-ups.	In	this	model,	the	patient	population	occupies	eight	states—four	living	states,	three	hospitalization	states,	and	a	death	state.	The	living	states	and	hospitalization	states	were	classified	by	the	number	of	previous	hospitalizations,	which	has	been	proved	to	be	a	significant	risk	factor	for	HF	re-hospitalization	and	mortality	[14].	Figure	1	presented	the	schematic	view	of	the	Markov	model.										The	model	starts	with	HF	patients	under	a	stable	condition,	and	then	moving	through	subsequent	cycles	of	being	alive,	hospitalized,	or	dead.	The	cycle	length	is	one	month.	We	selected	time	horizon	of	10	years	as	most	of	our	cohort	died	within	8	years.	At	the	end	of	each	month,	patients	transited	into	the	next	state,	according	to	the	transitional	probabilities	of	hospitalization	and	death	at	the	current	state.	Patients	in	states	other	than	death	might	continue	to	live,	get	hospitalized,	or	die	from	cardiovascular	or	non-cardiovascular	causes	at	the	next	cycle.	We	assumed	that	the	relative	risks	(RRs)	in	each	intervention	program	compared	to	UC	stay	consistent,	and	the	risks	of	hospitalization	and	mortality	become	constant	after	3	times	of	hospitalization.	
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Input	data									The	input	parameters	were	derived	from	literature	reviews	(Table	1).	To	examine	the	cost-effectiveness	of	MMP	and	ETP	in	HF,	several	groups	of	input	data	were	needed—hospitalization	rate	and	mortality	rate	in	UC	at	a	living	state	with	no	previous	hospitalization,	in-hospital	mortality	rate	with	no	previous	hospitalization,	relative	risks	(RRs)	of	hospitalization	and	mortality	in	MMP	and	ETP	comparing	to	the	risks	in	UC,	RRs	of	hospitalization	and	mortality	with	previous	hospitalizations	comparing	to	the	risks	without	previous	hospitalization,	and	costs	of	UC,	MMP,	and	ETP.	The	costs	of	intervention	programs	incurred	at	the	beginning	of	the	follow-up,	the	costs	of	hospitalization	incurred	at	every	hospitalization,	and	the	costs	of	outpatient	care	and	wage	losses	were	counted	continuously	throughout	the	follow-up.	We	assumed	the	costs	of	outpatient	care,	which	was	one	of	the	major	costs	in	UC,	were	the	same	in	the	three	programs,	as	the	the	components	in	UC	were	also	contained	in	the	intervention	programs.	Wage	loss	only	occurred	in	ETP,	since	patients	in	this	program	have	lost	working	hours	for	exercising.	A	discount	rate	of	5%	was	used	to	calculate	total	costs,	which	were	converted	to	the	amount	incurred	at	the	beginning	of	follow-up.	The	input	data	used	in	this	study	came	from	the	results	of	several	published	literature	reviews,	as	shown	in	Table	1.	The	original	hospitalization	and	mortality	rates	from	the	reviews	were	converted	into	monthly	probabilities	to	perform	the	analyses.		
	 Estimate	 95%	confidence	
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interval	
Hospitalization	rate	with	no	previous	hospitalization	UC	[10]	 0.008	 0.006	–	0.011	
RR	of	hospitalization	with	previous	hospitalizations	[14]	1*	 1.28	 1.23	–	1.33	2	 3.32	 3.21	–	3.43	
Mortality	rate	with	no	previous	hospitalization	UC	[10]	 0.007	 0.006	–	0.009	
In	hospital	mortality	UC	[15]	 0.154	 0.105	–	0.202	
RR	of	mortality	with	previous	hospitalizations	[16]	1	 1.22	 1.14	–	1.30	2	 1.33	 1.20	–	1.47	3	 1.64	 1.40	–	1.91	
RR	of	hospitalization	MMP	[5]	 0.73	 0.66	–	0.82	ETP	[17]	 0.61	 0.46	–	0.80	
RR	of	mortality	MMP	[5]	 0.83	 0.70	–	0.99	ETP	[9]	 0.64	 0.40	–	1.02	
Costs	($/patient)	**	
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MMP	implementation	costs	[10]	 826	 660	–	991	
ETP	implementation	costs	[13]	 2,020	 1,610	–	2,428	
Outpatient	HF	care	costs	for	all	[10]	 1,871	 1,497	–	2,245	
Wage	loss	in	ETP	[13]	 3,648	 2,918	–	4,378	
Hospitalization	cost	per	stay	[13]	 11,413	 9,130	–	13,696	
Table	1.	Input	data:	probabilities,	RRs,	and	costs.	*	Number	of	previous	hospitalizations	**	All	costs	are	converted	into	2015	U.S.	dollar.	***	The	total	costs	of	interventions	are	the	costs	of	intervention	programs	plus	the	cost	of	UC.		
Cost-effectiveness	analysis	and	sensitivity	analyses									The	life-years	of	patients	and	corresponding	costs	in	each	group	were	obtained.	We	calculated	ICERs	as	cost	per	life-year	saved.	Sensitivity	analyses	were	performed	to	examine	the	robustness	of	the	results	and	address	the	uncertainty	in	the	input	data.	We	conducted	one-way	sensitivity	analysis	on	the	variables	within	clinically	plausible	ranges	on	our	baseline	estimates	(Table	1).	In	the	probabilistic	sensitivity	analysis,	Monte	Carlo	simulation,	implemented	with	Metropolis-Hasting	algorithm	[18],	was	used	to	generate	10,000	trials	of	follow-ups,	in	which	each	parameter	was	sampled	from	a	specified	distribution	(beta	distribution	for	probabilities	and	log-normal	distribution	for	RRs)	within	
	 7	
its	plausible	range.	Each	trial	yielded	an	ICER	for	each	comparison	pairs,	and	the	distributions	of	the	ICERs	and	the	cost-acceptance	curve	from	the	10,000	trials	were	examined	at	the	end.				
Results	
Base-case	analysis			 UC	 MMP1	 ETP2		Costs	($)	 10,694	 12,007	 37,635	Live-year	saved	 6.75	 7.12	 7.93	Incremental	costs	($)	 	 1,313	 25,628	Incremental	life-year	saved	 	 0.37	 0.81	Incremental	C/E	($/life-year	saved)	 	 3,535	 31,624	Table	2.	Cost-effectiveness	of	MMP	and	ETP.	1:	MMP	vs.	UC	2:	ETP	vs.	MMP										Table	2	summarizes	aggregate	results	out	of	a	possible	patient	population	under	UC,	MMP,	and	ETP	for	a	10-year	follow-up	period.	Patients	under	UC	lived	an	average	of	6.75	years	and	accrued	$10,694	in	healthcare	cost	per	patient.	Under	intervention	programs,	these	same	patients	lived	an	average	of	7.12	years	per	patient	in	MMP	and	7.93	years	per	patient	in	ETP,	and	cost	$12,007	per	patient	in	MMP	and	$37,635	per	patient	in	ETP.	Therefore,	MMP	increased	the	patients’	life	expectancy	by	0.37	years	per	patient	with	an	additional	$13,13	of	healthcare	costs	per	patient	as	compared	to	UC,	and	ETP	achieved	a	
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0.81-year	of	life-year	increase	for	$25,628	additional	cost	per	patient	as	compared	to	MMP.	The	ICERs	were	$3,535	per	life-year	saved	in	MMP	compared	to	UC	and	$31,624	per	life-year	saved	in	ETP	compared	to	MMP.			
One-way	sensitivity	analysis	
One-way	sensitivity	analysis	
UC	vs.	MMP	
	
																																																																																																ICER	($/Life-year	saved)	
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One-way	sensitivity	analysis	
MMP	vs.	ETP	
	
																																																																																																						ICER	($/Life-year	saved)	Figure	2.	One-way	sensitivity	analysis.										Figure	2	shows	the	one-way	sensitivity	analysis,	in	which	one	of	the	input	parameters	was	changed	each	time,	within	its	plausible	range.	The	ICER	of	MMP	as	compared	to	UC	ranged	from	$1,307	to	$4,743	per	life-year	saved,	with	the	parameter	change	in	either	UC	or	MMP.	The	ICER	of	ETP	as	compared	to	MMP	ranged	from	$16,043	to	$42,397	per	life-year	saved,	with	the	parameter	change	in	either	MMP	or	ETP.				
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Probabilistic	sensitivity	analysis	
	Figure	3.	Cost-effectiveness	acceptability	curve										In	the	probabilistic	sensitivity	analysis,	the	median	ICER	of	MMP	comparing	to	UC	was	$3,718	per	life-year	saved,	and	the	median	ICER	of	ETP	comparing	to	MMP	was	$30,006	per	life-year	saved.	The	cost-effectiveness	acceptability	curves	(Figure	3)	show	that	UC	is	the	most	cost-effective	option	when	the	willingness	to	pay	is	lower	than	$4,050	per	life-year	saved,	MMP	becomes	the	most	cost-effective	one	when	the	budget	is	more	than	$4,015	but	less	than	$29,697,	and	when	the	budget	is	more	than	$29,697	per	life-year	saved,	ETP	is	the	most	cost-effective	strategy.			
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Discussion									MMP	has	been	a	widely	studied	and	adopted	intervention	program	that	provides	HF	patients	continuous	disease	education,	as	well	as	social	and	psychological	support.	ETP	serves	as	a	more	advanced	intervention	program	that	integrates	the	basic	elements	in	MMP	with	regular	exercise	training	to	improve	HF	prognosis.	There	is	evidence	from	multiple	resources	that	MMP	and	ETP	can	increase	the	survival	of	HF	patients	in	a	cost-effective	way	by	reducing	hospitalization	and	mortality	[5,	11,	19,	20].	However,	the	cost-effectiveness	of	the	two	intervention	programs	was	studied	individually	and	no	direct	comparison	has	been	made	between	them.										This	study	confirmed	the	cost-effectiveness	of	MMP	and	ETP	for	treating	HF	patients.	MMP	was	found	to	prolong	the	survival	of	HF	patients	and	at	an	expected	cost	of	$3,535	per	life-year	saved,	and	ETP	further	increased	survival	at	an	expected	cost	of	$31,624	per	life-year	saved.	With	an	incremental	survival	of	0.81	years	as	compared	to	MMP,	ETP	yielded	much	higher	costs	due	to	the	wage	loss,	in	addition	to	the	costs	of	implementing	the	program,	of	patients	participated	in	the	program,	which	were	not	offset	by	the	reduced	hospital	costs.	Nevertheless,	the	results	of	both	the	two	intervention	programs	lie	within	a	reasonable	range	of	cost-effectiveness	in	improving	HF	patients’	survival.	Furthermore,	this	analysis	used	life-year	saved	as	the	effectiveness	measurement	and	did	not	incorporate	quality	of	life,	while	evidences	have	been	showing	that	MMP	and	ETP	improve	quality	of	life	in	HF	patients;	our	estimates	are	therefore	conservative	in	assessing	the	effectiveness	of	the	two	intervention	programs[5,	17].	To	our	knowledge,	this	is	by	far	the	first	analysis	that	took	the	two	intervention	programs	together	into	consideration	and	assessed	the	cost-
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effectiveness	acceptability	of	the	programs,	so	that	provided	more	nuanced	information	for	deciding	an	optimal	intervention	for	HF	patients	given	a	broad	range	of	willing-to-pay	threshold.									There	are	still	some	limitations	in	this	analysis	due	to	the	data	source	and	model	assumptions.	First	of	all,	the	input	data	of	the	three	arms	(UC,	MMP,	and	ETP)	in	this	analysis	came	from	multiple	literature	reviews	[5,	9,	10,	13,	17],	therefore	it	is	possible	that	the	HF	patients	from	these	different	sources	were	not	exactly	under	the	same	condition	when	being	included	in	the	study.	The	hospitalization	and	mortality	data	of	MMP	came	from	the	same	review	study	[5],	while	the	data	of	ETP	were	extracted	from	two	studies	[9,	17],	since	neither	of	the	two	studies	alone	provided	complete	input	data	for	our	analysis.	The	study	populations	were	all	elder	HF	patients	in	developed	countries,	but	some	demographic	factors,	such	like	gender,	race,	income,	and	education	level,	were	not	adjusted	and	might	have	generated	differences	in	the	outcomes	among	those	patients.	This	analysis	assumed	that	MMP	and	ETP	applied	to	the	same	group	of	patients,	while	it	is	possible	that	some	HF	patients	in	severer	conditions	were	not	able	to	take	ETP	but	could	only	accept	MMP.	The	study	population	in	ETP	reviews	was	patients	with	low-to-medium	risk	(New	York	Heart	Association	(NYHA)	class	II	and	III)	and	at	a	median	age	of	60	[17],	while	the	population	in	MMP	studies	was	HF	patients	discharged	from	hospital	and	at	a	median	age	of	70	[5].	In	that	case,	patients	who	were	able	to	participate	in	ETP	were	healthier,	younger,	and	at	lower	risks	of	hospitalization	and	death	compared	to	those	who	took	MMP,	posing	a	potential	bias	in	this	comparison	between	MMP	and	ETP.	These	limitations	might	affect	the	generalization	of	the	results	in	this	analysis,	and	further	studies	are	needed	to	generate	more	valid	data	source	and	more	robust	analytical	models.		
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Conclusion									This	cost-effectiveness	analysis	confirms	the	improvement	in	survival	of	HF	patients	under	MMP	and	ETP,	and	compares	the	cost-effectiveness	and	acceptability	of	the	two	programs.	ETP	generated	higher	life-year	saving	for	higher	costs	than	MMP	did.	MMP	was	the	most	cost-effective	way	with	low	willing-to-pay	threshold	(between	$4,015	and	$29,697	per	life-year	saved),	while	ETP	was	reasonably	cost-effective	when	the	society	is	willing	to	pay	more	than	$29,697	per	life-year	saved.											
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